Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Bintie Biotechnology

Request full access

A clinical-stage biomedical technology innovation enterprise

ChinaFounded 2021Biotech & Life Sciences

About Shanghai Bintie Biotechnology

Immuxell is a biotechnology company specializing in the development of bispecific T Cell Engagers to combat cancer. Utilizing its proprietary TETHER platform, Immuxell creates off-the-shelf biologics that redirect and activate the body's own T cell immune response towards cancer cells expressing specific oncogenic driver targets. The company's advanced affinity maturation capabilities and biotherapeutic technologies produce T Cell Engagers with balanced CD3 binders and extended half-life, aiming for sustained T cell responses against solid tumors. Immuxell serves patients with advanced solid tumors, leveraging scientific advancements in gene editing, synthetic biology, and cell therapies to deliver potentially curative treatments. The business operates in the oncology therapeutics market, primarily targeting oncogenic driver mutations like KRAS, which are crucial for tumor growth and maintenance. Immuxell generates revenue through the development and commercialization of its proprietary therapies, as well as potential partnerships and licensing agreements.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
17.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2023 $14M $55M Huangpu Pharmaceutical Fund · SDIC Venture Capital · GSR United Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Bintie Biotechnology website traffic

Latest recorded traffic for Shanghai Bintie Biotechnology is 1.2K monthly website visits, up 150% over the last three months.

Latest monthly visits1.2K 3-month web change+150%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Bintie Biotechnology in its local ecosystem

Live from Dealroom

The Shanghai Bintie Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Huangpu Pharmaceutical Fund
  • SDIC Venture Capital
  • GSR United Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Bintie Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Bintie Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.